Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout. The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!